Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 13atezolizumab 9Specimen Handling 9durvalumab 8Nivolumab 7Magnetic Resonance Spectroscopy 7tremelimumab 6lenvatinib 6cabozantinib 4Sorafenib 4tislelizumab 3donafenib 3X-Rays 3Surgical Procedures, Operative 3Oxaliplatin 3Ipilimumab 3Immunotherapy 3Fluorouracil 3ulixertinib 2sintilimab 2sapanisertib 2relatlimab 2pembrolizumab 2camrelizumab 2apatinib 2Leucovorin 2Irinotecan 2Fluorodeoxyglucose F18 2Doxorubicin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × guadecitabine × 30 days × Clear all
NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡